Beata Jagielska

Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate – The impact of fibrosarcomatous transformation

Piotr Rutkowski, Anna Klimczak, Iwona Ługowska et al. · European Journal of Surgical Oncology · 2017 · 85 citations · Full text

Medicine, Dermatology, Oncology +10

PD-L1 Overexpression, SWI/SNF Complex Deregulation, and Profound Transcriptomic Changes Characterize Cancer-Dependent Exhaustion of Persistently Activated CD4+ T Cells

Iga Jancewicz, Joanna Szarkowska, Ryszard Konopiński et al. · Cancers · 2021 · 43 citations · Full text

Life Sciences, Immunology, Oncology +17

Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology

Denis Horgan, Gennaro Ciliberto, PierFranco Conte et al. · Biomedicine Hub · 2020 · 37 citations · Full text

Medicine, Health Policy, Oncology +15

Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 Years

Aneta Mela, Łukasz A. Poniatowski, Bartłomiej Drop et al. · Frontiers in Pharmacology · 2020 · 29 citations · Full text

Public Affairs, Pharmaceutical Policy, Pharmacoeconomics +17

Time for Change? The Why, What and How of Promoting Innovation to Tackle Rare Diseases – Is It Time to Update the EU’s Orphan Regulation? And if so, What Should be Changed?

Denis Horgan, Barbara A. Moss, Stefania Boccia et al. · Biomedicine Hub · 2020 · 21 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacology +17